Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Multimeric-001 Influenza Vaccine in Healthy Volunteers
NCT01146119Phase 2Completed
- Sponsor
- Scinai Immunotherapeutics Ltd.
- Start
- Jul 2010
- Primary completion
- May 2011
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of multimeric-001 in influenza (6 arms), sponsored by Scinai Immunotherapeutics Ltd. Primary endpoints: Number of Participants with Adverse Events as a Measure of Safety and Tolerability and Anti Multimeric-001 antibodies. Started Jul 2010; status: completed.
02
Drugs
multimeric-001
03
Conditions
influenza
Beyond the preview
Go deeper on NCT01146119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01146119.